

Swiss Friends of Oxford University and Jesus College Oxford request the pleasure of your company at a special breakfast for members and guests

DATE

Sunday, 18th September 2022

TIME

09:30–11:00

RSVP

by Wednesday, 7th September 2022

To Helen Baumgartner

Swiss Friends of Oxford University

E info@oxfordfriends.ch

T +41 41 760 64 66

LOCATION

**Jesus College, Mansell Room, First Quad,
Staircase V, first floor**

AGENDA

09:30

Welcome by Dr Brittany Wellner James, Director of Development and Fellow and Howard Rosen, President SFOU

09:40

Presentation by Professor Georg A Holländer, Professorial Fellow in Developmental Medicine, Botnar Institute

10:10

Q&A

11:00

Optional private tour: New Cheng Yu Tung Building, Tower Room and Digital Hub, led by Dr Brittany Wellner James



PROFESSOR GEORG A HOLLÄNDER



Professor Georg Holländer is the Hoffmann and Action Medical Research Professor of Developmental Medicine and Head of the Department of Paediatrics at the University of Oxford. He is also the Director of the Botnar Research Centre of Child Health in Basel, Switzerland. Trained in Paediatrics and experimental immunology he held in the past academic positions at Harvard Medical School and was the director of research at Basel University's Children's Hospital. Since 2010 he shares his work and time between Oxford und Basel where he supervises research labs focusing on the developmental immunobiology of the thymus. He received the Fanconi Prize of the Swiss Society for Paediatrics in 2009, was chosen a corresponding member of the Swiss Academy of Medical Sciences in 2012, and elected as a Fellow of the Academy of Medical Sciences in the UK.

At the **Institute of Developmental and Regenerative Medicine (IDRM)**, Professor Holländer leads the **Holländer Group in Immunology**. The IDRM is a unique flagship institution, at the University of Oxford, dedicated to meeting an ambitious challenge: two thirds of all deaths world-wide are due to non-communicable diseases, many of which are cardiovascular, neurological or immune system disorders that have a developmental origin, representing an urgent unmet clinical need. The mission of the IDRM is the development of new drugs and therapeutic strategies to tackle these chronic illnesses. To achieve these goals the IDRM will combine experimental and computational biology with machine learning, artificial intelligence platforms and mathematical modelling; working across disciplines with University colleagues in **Big Data, Target Discovery, Maths** and **Biomedical Engineering** and with clinicians at the John Radcliffe and Churchill Hospitals in Oxford.